JP Morgan Chase
SGTX

JP Morgan Chase’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

JP Morgan Chase’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,752
Closed -$148K – 7085
2022
Q1 		$148K Sell
7,752
-442
-5% -$9.85K ﹤0.01% 5333
2021
Q4 		$294K Sell
8,194
-402
-5% -$22.9K ﹤0.01% 5146
2021
Q3 		$632K Sell
8,596
-517
-6% -$39.8K ﹤0.01% 4591
2021
Q2 		$1.27M Sell
9,113
-1,377
-13% -$242K ﹤0.01% 4125
2021
Q1 		$3.05M Buy
+10,490
New +$4.17M ﹤0.01% 3386

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's SGTX Position: Q2 2022 in Review

JP Morgan Chase sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 7,752 shares — an estimated $148K sold.

JP Morgan Chase first reported a position in SGTX in Q1 2021 and held it in 5 quarters. The position peaked at $3.05M in Q1 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • JP Morgan Chase reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • JP Morgan Chase sold 7,752 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $148K.
  • JP Morgan Chase first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • JP Morgan Chase's Sigilon Therapeutics, Inc. Common Stock position peaked at $3.05M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.